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Abstract. Capecitabine is a commonly used anticancer drug, 
which has been associated with adverse events, including 
skin and gastrointestinal symptoms, such as vomiting 
and diarrhea. We herein present treated two rare cases of 
capecitabine-associated ileitis. In one of the patients, ileitis 
occurred during combination chemotherapy for metastatic 
colon cancer, despite previous good tolerance to this drug; the 
other patient developed ileitis following adjuvant single-agent 
treatment. The first case is unlike previously reported cases, 
in which patients had no past exposure to capecitabine. Ileitis 
may be severe but reversible with early diagnosis and proper 
supportive treatment, and patients may resume chemotherapy 
following capecitabine discontinuation.
Introduction
Capecitabine is an oral fluorouracil (FU) prodrug commonly 
used in patients with colorectal cancer, particularly as adju-
vant and palliative chemotherapy in colon cancer (1). The 
most common gastrointestinal adverse events include nausea, 
vomiting and diarrhea. Capecitabine may also cause serious 
gastrointestinal adverse events, such as intestinal perforation 
or obstruction (1).
We treated 2 patients with ileitis associated with 
capecitabine administration. In one of the patients, ileitis 
occurred during palliative second-line combination chemo-
therapy for metastatic colon cancer, despite good tolerance to 
capecitabine during previous chemotherapy. A literature search 
identified no previous reported cases among Chinese adults 
who had received capecitabine as second-line chemotherapy. 
The other patient developed ileitis while on single-agent 
adjuvant therapy with capecitabine for sigmoid colon cancer. 
The purpose of this study was to present the case histories, 
pathophysiology, imaging findings and literature review for 
this uncommon condition.
Case reports
Case 1. A 61-year-old Chinese woman underwent laparo-
scopic right hemicolectomy for cancer of the ascending colon. 
On pathological examination, the tumor was diagnosed as 
moderately differentiated adenocarcinoma, stage pT4aN1aM0, 
KRAS wild-type. The patient completed 6 months of adjuvant 
capecitabine and oxaliplatin treatment, with good tolerance.
The carcinoembryonic antigen (CEA) levels increased, 
and a positron emission tomography/computed tomography 
(PET̸CT) scan at 4 months after treatment revealed lung and 
liver metastases. The patient was treated with capecitabine and 
irinotecan (CAPIRI) and cetuximab (every 2 weeks). After 
5 cycles, treatment was changed to CAPIRI and bevacizumab 
(every 2 weeks), as a follow‑up PET̸CT scan revealed disease 
progression. The patient exhibited a good clinical response, 
with a decrease in abdominal pain; the CEA level decreased 
from 82.1 to 18.4 ng/ml. However, on day 9 of cycle 4 of 
CAPIRI and bevacizumab, the patient was admitted with 
right lower quadrant abdominal pain, watery diarrhea and 
vomiting. The patient also developed fever and the blood tests 
revealed neutropenia (nadir neutrophil count, 0.3x109/l) and 
hypokalemia. The liver function tests were within normal 
limits. The differential diagnosis included infectious gastro-
enteritis aggravated by neutropenia and bevacizumab‑related 
bowel perforation. The patient was treated conservatively with 
intravenous fluids, broad-spectrum antibiotics and granulocyte 
colony‑stimulating factor (G‑CSF). The fever subsided 1 day 
later and the neutrophil count increased to >0.5x109/l.
A CT scan of the abdomen and pelvis revealed extensive 
submucosal edema at the terminal and middle part of the ileum, 
associated with adjacent increase in fat stranding (Fig. 1). There 
was no pneumoperitoneum or bowel dilation. Evaluation was 
negative for sepsis, including blood, stool and urine cultures.
Hypokalemia persisted for 1 week and was managed with 
intravenous fluids and dietary modifications. The patient's 
condition gradually improved with conservative treatment, 
with improvement in oral intake and decreased vomiting and 
diarrhea. The patient remained in the hospital for a total of 
12 days. The final diagnosis was terminal ileitis associated 
with capecitabine.
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Chemotherapy with irinotecan and bevacizumab was 
resumed 1 week after hospital discharge, with no recurrence of 
ileitis. A CT scan performed 2 months later revealed complete 
resolution of the small bowel wall submucosal edema (Fig. 2).
Case 2. A 59-year-old Chinese woman underwent laparoscopic 
sigmoidectomy for sigmoid colon cancer. On pathological 
examination, the tumor was diagnosed as pT3N0 adenocar-
cinoma with extramural vascular invasion. The patient was 
started on adjuvant capecitabine (2,500 mg/m2/day orally 
on days 1-14 every 3 weeks) and exhibited good tolerance to 
chemotherapy during the first 2 cycles; however, she developed 
grade 1 diarrhea, hand-foot-skin reaction and stomatitis.
After day 14 of cycle 3, the patient exhibited worsening 
diarrhea, and was admitted to the hospital on day 19 after chemo-
therapy initiation; she had grade 3 mucositis, hand-foot-skin 
Figure 1. Case 1. Computed tomography scan. Axial view showing submu-
cosal edema associated with adjacent increase in fat stranding. The bowel 
loops were not dilated.
Figure 2. Case 1. Computed tomography scan. Axial view showing complete 
resolution of small bowel wall submucosal edema.
Figure 3. Case 2. Computed tomography scan. Axial view showing submu-
cosal edema involving the distal to terminal ileum, with surrounding fat 
stranding, consistent with ileitis. Mucosal enhancement was preserved.
Figure 4. Case 2. Computed tomography scan. Coronal view showing mul-
tiple small gas bubbles along the edematous distal ileum, consistent with 
pneumatosis intestinalis.
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reaction, grade 4 diarrhea and severe generalized abdominal 
pain. A contrast-enhanced CT scan of the abdomen revealed 
diffuse submucosal edema with surrounding fat stranding, 
suggestive of ileitis in a long segment of the distal ileum to 
the terminal ileum. Multiple small gas bubbles were observed 
along the wall of the edematous distal ileum, consistent with 
pneumatosis intestinalis (Figs. 3 and 4).
The patient was admitted to the intensive care unit for close 
monitoring and received total parenteral nutrition due to diar-
rhea, hypoalbuminemia and decreased oral intake. Inotropic 
support and electrolyte replacement were given to maintain 
hemodynamic stability and avoid electrolyte disturbances.
The patient exhibited a decreased neutrophil count 
(minimum, 0.7x109/l on day 20) and developed fever on day 21. 
Evaluation was negative for sepsis, including blood, stool and 
urine cultures. The patient was treated with broad-spectrum 
antibiotics for a total of 10 days and G‑CSF. The neutrophil 
count increased to 1.39x109/l after 2 days.
The patient's condition gradually improved and diarrhea 
subsided on day 29 after chemotherapy initiation. The muco-
sitis and skin reaction resolved and parenteral nutrition was 
discontinued after 16 days.
Discussion
The two patients developed ileitis associated with capecitabine. 
Previously reported cases of capecitabine‑associated ileitis 
included 1 patient who had received adjuvant capecitabine 
monotherapy for colon cancer, 1 patient who had received 
capecitabine, oxaliplatin and bevacizumab for metastatic 
rectal cancer, and 1 patient who had received capecitabine 
and oxaliplatin for metastatic rectal cancer (2‑4). In these 
previous cases, the ileitis dveloped early, between the first 
and third cycle of chemotherapy, and none of the patients in 
these reports had previous exposure to capecitabine. Case 1 
highlights the fact that small bowel complications may occur 
during later cycles of chemotherapy, despite previous good 
tolerance to capecitabine.
In both presented cases, it was difficult to confirm the 
diagnosis, as the initial clinical findings were non-specific, 
the patients were on combination chemotherapy plus targeted 
therapy, and this type of toxicity is rare. The CT scan was an 
important tool for diagnosis and monitoring. The radiographic 
findings were comparable in the two cases, and ileitis was 
observed as diffuse submucosal edema of the small bowel 
wall, which was consistent with previous case reports and 
confirmed the diagnosis.
It was important to closely monitor serum electrolyte levels 
during the acute phase of the ileitis. Adequate hydration was 
also important, as capecitabine is excreted primarily by the 
kidneys.
Capecitabine is administered as an oral prodrug; it is 
metabolized in successive enzymatic steps to 5‑FU, which is 
metabolized into two active metabolites that exert the cyto-
toxic effect. The step of conversion to 5‑FU preferentially 
occurs in tumor tissues (1). 5‑FU may cause vasospasm in 
the coronary vessels and cardiotoxicity (5). Furthermore, the 
vascular endothelium is susceptible to 5‑FU via the generation 
of free radicals. The endothelial damage may cause a proco-
agulant state and thrombosis (6,7). These vascular effects of 
5‑FU may also affect intestinal vessels. A previous case of 
5‑FU‑associated small bowel vasculitis due to arterial isch-
emia has been reported (8). Another study demonstrated that 
proinflammatory cytokines may contribute to 5‑FU‑associated 
intestinal mucosal injury (9).
In our cases, the contribution of bevacizumab and 
irinotecan to ileitis was unlikely. According to a previous 
case series, the most common clinical findings in bevaci-
zumab‑associated bowel perforation include abdominal pain 
and tenderness, vomiting, fever and leukocytosis. Diarrhea has 
been less frequently reported in most bevacizumab studies and 
is not a typical symptom of bowel perforation (10). A literature 
search identified no reported cases of small bowel ileitis asso-
ciated with bevacizumab and irinotecan administration. The 
patient in case 1 did not have another episode of ileitis during 
subsequent cycles of irinotecan and bevacizumab treatment 
following discontinuation of capecitabine.
In summary, we presented two cases of adult Chinese 
patients who developed ileitis associated with capecitabine 
treatment. Ileitis may occur despite previous good tolerance to 
capecitabine. A high index of suspicion is crucial for prompt 
diagnosis. Ileitis may be reversible with early recognition, 
close monitoring and proper supportive treatment.
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